Takeda to sell a subsidiary of business for general consumers such as cold medicine

Takeda to sell subsidiary of consumer business such as cold medicine 13:11 on August 20

Takeda Pharmaceutical Co., Ltd. is proceeding with adjustments to sell a subsidiary of a business for general consumers known for its vitamin drug “Alinamine” and cold medicine “Benza Block” to an American investment fund for about 250 billion yen. I found out that In the future, we aim to concentrate management resources on businesses for highly profitable medical institutions, such as the development of anticancer drugs.

According to the people involved, Takeda Pharmaceutical Co., Ltd. is a subsidiary of Takeda Consumer Healthcare, a subsidiary that manufactures and sells medicines for general consumers such as vitamin drug Alinamine and cold medicine Benzabloc, an American investment fund We are making adjustments to sell to the Blackstone Group for about 250 billion yen.

Takeda said that the domestic drug market for general consumers could not expect significant growth due to population decline, etc. Our policy is to concentrate management resources on businesses for highly profitable medical institutions, such as the development of therapeutic drugs.

Last year, Takeda acquired Irish pharmaceutical giant Shire for a record 6 trillion yen, which is the largest overseas acquisition by a Japanese company, but the interest-bearing debt swelled and the financial position improved. We are proceeding with the sale of assets.